Madrigal Pharmaceuticals

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $1.28 billion, up 146% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to September 30, 2025: −$0.16 billion.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to September 30, 2025: $0.00 billion.SEC EDGAR filings (XBRL)
• Latest earnings call or results release (July 30, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
• Latest annual report (filed February 19, 2026): 5 risk factors added, 2 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $8.0 million on the open market.SEC Form 4
• 413 institutional managers reported a position at June 30, 2026 (+33 on the quarter before).SEC Form 13F
• H-1B filings certified in Q4 2021: 1.U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Madrigal Pharmaceuticals yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (CAPITOL COUNSEL LLC)third_quarter 2026 · $0.1 million
2. Oct 19, 2026Lobbying
   Lobbying report (MADRIGAL PHARMACEUTICALS, INC.)third_quarter 2026 · $0.3 million
3. Oct 19, 2026Lobbying
   Lobbying report (CROSSROADS STRATEGIES, LLC)third_quarter 2026 · $0.1 million
4. Oct 18, 2026Lobbying
   Lobbying report (BALLARD PARTNERS)third_quarter 2026 · $0.1 million
5. Aug 12, 20268-K
   Director or officer changeItem 5.02
6. Jul 20, 2026Lobbying
   Lobbying report (MADRIGAL PHARMACEUTICALS, INC.)second_quarter 2026 · $0.4 million
7. Jul 20, 2026Lobbying
   Lobbying report (CROSSROADS STRATEGIES, LLC)second_quarter 2026 · $0.1 million
8. Jul 16, 2026Lobbying
   Lobbying report (CAPITOL COUNSEL LLC)second_quarter 2026 · $0.1 million
9. Jul 15, 2026Lobbying
   Lobbying report (BALLARD PARTNERS)second_quarter 2026 · $0.1 million
10. Jun 30, 2026Patent
    Patent granted: METHODS FOR TREATING A FATTY LIVER DISEASEUS 12667575
11. Jun 23, 2026Patent
    Patent granted: RESMETIROM FOR REDUCING LIVER VOLUMEUS 12661361
12. Jun 23, 2026Patent
    Patent granted: THERAPEUTIC COMBINATIONS OF ROSUVASTATIN AND RESMETIROM FOR THE TREATMENT OF LIVER DISORDERS OR LIPID DISORDERSUS 12661359
13. Jun 17, 20268-K
    Director or officer changeItem 5.02
14. Jun 17, 20268-K
    Shareholder vote resultsItem 5.07
15. Apr 28, 20268-K
    Director or officer changeItem 5.02
16. Feb 19, 202610-K
    Annual report (10-K)5 risk factors added, 2 removed
17. Jan 30, 20268-K
    Material agreement signedItem 1.01
18. Dec 11, 20258-K
    Director or officer changeItem 5.02
19. Aug 5, 2025Patent
    Patent granted: METHODS FOR TREATING A FATTY LIVER DISEASEUS 12377104
20. Jul 22, 20258-K
    Material agreement signedItem 1.01
21. Jul 22, 20258-K
    Material agreement terminatedItem 1.02
22. Jun 20, 20258-K
    Shareholder vote resultsItem 5.07
23. Apr 17, 20258-K
    Director or officer changeItem 5.02
24. Mar 11, 20258-K
    Director or officer changeItem 5.02
25. Feb 26, 202510-K
    Annual report (10-K)26 risk factors added, 6 removed
26. Feb 28, 202410-K
    Annual report (10-K)7 risk factors added, 1 removed
27. Nov 7, 2023Patent
    Patent granted: METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONISTUS 11806353

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1157601